Adding ribociclib, a targeted drug that disrupts cancer cells, to standard hormone therapy was found to boost survival among premenopausal patients who have an advanced form of the disease. The research, led by Dr Sara Hurvitz of the University of California in Los Angeles, followed pre-menopausal women under the age of 59 who had advanced hormone receptor-positive, HER2-negative breast cancer. The patients were assigned either ribociclib, which targets and interferes with processes in the cells that cause cancer to grow, or a placebo. All the women also received hormone therapy. Women who received ribociclib lived an average of It is now absolutely fantastic to see the very first evidence that ribociclib can give thousands of younger women diagnosed with metastatic breast cancer more time to live.
Study estimates number of U.S. women living with metastatic breast cancer
Abortion and Cancer Risk
In a large Kaiser Permanente study of women with invasive breast cancer, socially integrated women -- those with the most social ties, such as spouses, community ties, friendships and family members -- were shown to have significantly lower breast cancer death rates and disease recurrence than socially isolated women. This study was published in the American Cancer Society journal Cancer. This is believed to be the largest study to date of social networks -- the web of personal relationships that surround an individual -- and breast cancer survival. Funded by the National Cancer Institute, the study included 9, women diagnosed with stages 1 to 4 invasive breast cancer enrolled in the After Breast Cancer Pooling Project, a pooled cohort of four studies of women with breast cancer, including one conducted at Kaiser Permanente Northern California. Data was collected and analyzed from breast cancer survivorship studies conducted in California, Utah, Oregon, Arizona, Texas and Shanghai, China. Researchers examined how a range of lifestyle factors -- including exercise, diet, weight management and social factors -- affect breast cancer survivorship.
Million Women Study
Transgender women male sex assigned at birth, female gender identity using hormone treatment show an increased risk of breast cancer compared with the general male population, finds a large Dutch study published by The BMJ today. The findings also show that transgender men female sex assigned at birth, male gender identity had a lower risk compared with the general female population. Although the risk in transgender women increased during a relatively short duration of hormone treatment , it is still lower than the general female population.
NCI-funded researchers are working to advance our understanding of how to prevent, detect, and treat breast cancer. They are also looking at how to address disparities and improve quality of life for survivors of the disease. MRI magnetic resonance imaging , ultrasound , and clinical breast exams are also used to detect breast cancer, but not as routine screening tools. Ongoing studies are looking at ways to enhance current breast cancer screening options.